ListedPVA QPPV.com application

ELIDEL / nasopharyngitis

United States · event evidence

nasopharyngitis

Listed

Increased over vehicle in the 1-year safety study; also among adverse events with increased incidence in the 6-week infant study.

Source evidence

Nasopharyngitis (26% vs. 21%), influenza (13% vs. 4%), pharyngitis (8% vs. 3%), viral infection (7% vs. 1%), pyrexia (13% vs. 5%), cough (16% vs. 11%), and headache (25% vs. 16%) were increased over vehicle in the 1-year safety study (see ADVERSE REACTIONS).
In the 6-week vehicle-controlled study these adverse events included pyrexia (32% vs. 13% vehicle), URI (24% vs. 14%), nasopharyngitis (15% vs. 8%), gastroenteritis (7% vs. 3%), otitis media (4% vs. 0%), and diarrhea (8% vs. 0%).

Return to label evidence explorer

Search products

Search by brand, active ingredient, INN or recorded alias.